Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting

Business Wire May 19, 2015

The Road To The Cure: 4 Biotech Stocks Advancing New Therapies In The Fight Against Cancer

Accesswire May 17, 2015

The Road To The Cure: 4 Biotech Stocks Advancing New Therapies In The Fight Against Cancer

Accesswire May 17, 2015

Verastem to Present at 2015 UBS Global Health Care Conference

Business Wire May 12, 2015

Verastem Reports First Quarter 2015 Financial and Corporate Results

Business Wire May 11, 2015

Verastem to Present at Upcoming Investor Conferences

Business Wire April 30, 2015

Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at the 2015 American Association of Cancer Research Annual Meeting

Business Wire April 22, 2015

Gelesis Closes $22M Equity Financing

PR Newswire March 26, 2015

Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting

Business Wire March 19, 2015

Small Biotec Firm Quietly Makes +1,000% Price Move

Accesswire March 17, 2015

Verastem Reports Year-End 2014 Financial Results

Business Wire March 10, 2015

Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of Certain Forms of Cancer

Accesswire March 9, 2015

Verastem to Present at 27th Annual ROTH Conference

Business Wire March 3, 2015

Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma

Business Wire February 12, 2015

Verastem Announces the Grant of Inducement Awards

Business Wire February 5, 2015

Verastem to Present at Upcoming Investor Conferences

Business Wire February 3, 2015

Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Business Wire January 29, 2015

Verastem Announces Pricing of Public Offering of Common Stock

Business Wire January 22, 2015

Verastem Announces Proposed Public Offering of Common Stock

Business Wire January 20, 2015

Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma

Business Wire January 20, 2015